Author

F. Y. Feng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 7 Research Focus:cell type annotation· 5 Research Focus:differential expression· 4 Research Focus:gene regulatory network inference· 4 Assay:bulk RNA-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

J. Chou· 3 shared A. Foye· 2 shared A. M. Bergman· 2 shared B. Wang· 2 shared E. J. Small· 2 shared H. van der Poel· 2 shared J. Yang· 2 shared M. Sjostrom· 2 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Chou

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

J. C.-Y. Tien, Y. Chang, Y. Zhang, J. Chou, Y. Cheng, X. Wang, J. Yang, R. Mannan, P. Shah, X.-M. Wang, A. J. Todd, S. Eyunni, C. Cheng, R. J. Rebernick, L. Xiao, , A. M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

bioRxiv · Mar 20, 2024Cancer Biology

Canonical AREs are tumor suppressive regulatory elements in the prostate

M. A. Augello, X. Chen, D. Liu, K. Lin, A. Hakansson, M. Sjostrom, F. Khani, L. D. Deonarine, Y. Liu, J. Travascio-Green, J. Wu, M. Loda, F. Y. Feng, B. D. Robinson, E. Davicioni, , C. Barbieri

This study identifies canonical AREs as tumor suppressive regulatory elements in prostate cancer, showing their reactivation can induce death in AR+ cancer cells and is linked to better prognosis.

bioRxiv · Feb 23, 2024 · PreprintCancer Biology

Integrative identification of non-coding regulatory regions driving metastatic prostate cancer

B. J. Woo, R. Moussavi-Baygi, H. Karner, M. Karimzadeh, K. Garcia, T. Joshi, K. Yin, A. Navickas, L. A. Gilbert, B. Wang, H. Asgharian, F. Y. Feng, H. Goodarzi

This study identifies non-coding regulatory regions driving metastatic prostate cancer using an integrative computational and experimental approach.

bioRxiv · Apr 14, 2023Cancer Biology

CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer

N. Zhao, k. Trepka, Y.-h. Wang, S. Chopra, N. Hooshdaran, H. Kim, J. Yang, J. Zhuo, S. Lim, K. K. Leung, E. Egusa, L. K. Zhang, A. Foye, J. Chou, F. Y. Feng, , R. Aggarwal

This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.

bioRxiv · Jun 17, 2021 · PreprintCancer Biology

Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states

H. Song, H. N. W. Weinstein, P. Allegakoen, M. H. Wadsworth, J. Xie, H. Yang, F. Y. Feng, P. R. Carroll, B. Wang, M. R. Cooperberg, A. K. Shalek, F. W. Huang

This study uses single-cell RNA-sequencing to analyze prostate cancer tumor microenvironment, identifying heterogeneous epithelial cell states and tumor-associated club cells.

bioRxiv · Nov 6, 2020Cancer Biology

Functional mapping of androgen receptor enhancer activity

C.-C. F. Huang, S. Lingadahalli, T. Morova, D. Ozturan, E. Hu, I. P. L. Yu, S. Linder, M. Hoogstraat, S. Stelloo, F. Sar, H. van der Poel, U. B. Altintas, M. Saffarzadeh, S. Le Bihan, B. McConeghy, , N. A. Lack

The paper functionally maps AR enhancer activity using STARRseq, finding most AR binding sites are inactive or constitutively active, with inducible enhancers forming regulatory hubs that drive gene transcription.

bioRxiv · Aug 18, 2020Cancer Biology

Human Prostate Cancer-Associated Macrophage Subtypes with Prognostic Potential Revealed by Single-cell Transcriptomics

J. C. Siefert, B. Cioni, M. J. Muraro, M. Alshalalfa, J. Vivie, H. van der Poel, F. Y. Feng, L. Wessels, W. Zwart, A. M. Bergman

The paper identifies three macrophage subtypes in human prostate cancer using single-cell transcriptomics and develops a gene signature linked to patient survival.

bioRxiv · Jun 19, 2020Immunology

Autoantibody landscape of advanced prostate cancer

W. S. Chen, W. A. Haynes, R. Waitz, K. Kamath, A. Vega-Crespo, R. Shrestha, M. Zhang, A. Foye, I. Baselga Carretero, I. Garcilazo Perez, M. Zhang, S. G. Zhao, M. Sjostrom, D. A. Quigley, J. Chou, , F. Y. Feng

This study characterizes the autoantibody landscape in metastatic castration-resistant prostate cancer using serum epitope repertoire analysis and identifies novel tumor-specific epitopes.

bioRxiv · May 2, 2020 · PreprintCancer Biology